SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing heightened community discussion driven by its pivotal role as infrastructure for real-world asset (RWA) tokenization and upcoming institutional integrations. Investors are debating its long-term potential as a foundational oracle network, with many focusing on its utility within the broader AI and decentralized finance ecosystems.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The Melania crypto token is currently trending amidst widespread investor backlash as the community discusses its significant decline from peak valuations and debates its legitimacy as a project versus a speculative scam. Many participants are actively calling out the association with political figures, fueling intense criticism regarding the risks of trading assets linked to high-profile family ventures.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently trending as members debate its long-term viability amidst institutional interest and recent listings, with some investors aggressively accumulating on dips while others express frustration over extended price stagnation. The community remains sharply divided between those citing quantum-resistant technology and potential regulatory clarity as bullish catalysts and others who view the ongoing token dilution as a primary headwind.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to its community's relentless focus on IRL brand-building initiatives and organic growth efforts. Participants are actively discussing their long-term conviction, showcasing various merchandise, and highlighting the project's permissionless structure as a unique differentiator in the current market.

iShares Trust - iShares 0-3 Month Treasury Bond ETF

iShares 0-3 Month Treasury Bond ETF

The community is actively using SGOV as a defensive "parking spot" for dry powder while waiting for better market entry points, driven by widespread concerns over persistent inflation, debt levels, and recession risks. Investors are favoring the ETF for its monthly income generation and capital preservation capabilities during this period of high macroeconomic volatility.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate its potential for institutional adoption against a backdrop of prolonged price decline and community frustration over leadership communication. Discussions are dominated by long-term holders adding to their positions despite skepticism, while many point to the need for clear regulatory progress and real-world payment volume to shift the project's current trajectory.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending as investors focus on its role in the AI data center infrastructure and its recent selection for significant CHIPS Act funding. The community is actively discussing the stock's potential for a short squeeze due to high short interest and its strategic partnerships, while debating whether upcoming earnings and commercial scaling will validate its long-term growth potential.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is trending following the launch of a Nasdaq-100 ETF intended to challenge Invescos market dominance, while simultaneously facing increased institutional and regulatory scrutiny over its expanding private credit business. Investors are closely monitoring the firm's strategic pivot into tokenized assets and ongoing capital accumulation, even as the stock price navigates recent market volatility and shifting institutional sentiment.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is trending as investors digest positive regulatory updates regarding the rolling BLA submission for its kidney disease treatment, povetacicept. The community is actively debating the company's long-term growth potential and pipeline diversification, while closely monitoring market reactions to recent clinical data.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is gaining market attention following positive coverage from Goldman Sachs and anticipation surrounding upcoming May data releases for their lead candidate, soquelitinib. The community is actively debating the stock's potential for a short squeeze, driven by significant short interest and bullish sentiment regarding the drug's oral efficacy compared to existing injectables in the immunology space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead

TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.


Why Is Tempus AI Stock Surging on Friday?

Tempus AI Inc. (NASDAQ: TEM) stock jumped on Friday, August 7, 2026, following strong AI healthcare peer earnings from Doximity Inc. and a strategic lab expansion with CellCarta.read more...

Can Weight-Loss Momentum Lift Hims & Hers Stock Before Q2 Earnings?

HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.

CellCarta Adds Tempus to CDx Commercialization Lab Network

CellCarta Adds Tempus to CDx Commercialization Lab Network CellCarta Adds Tempus to CDx Commercialization Lab Network PR Newswire MONTREAL, Aug. 6, 2026 Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model.MONTREAL...

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft, can...

TEM Q2 Loss Narrower Than Expected, Revenues Beat, Stock Up

Tempus AI climbs 6.6% after its second-quarter loss narrows, revenues beat estimates and 2026 sales guidance rises on diagnostics and data growth.

Compared to Estimates, Tempus (TEM) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates

Tempus (TEM) delivered earnings and revenue surprises of +69.23% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

This account has been verified as an official TEM representative.

Verified Account

Tempus AI

$TEM Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.03 up 112.00% YoY
• Reported revenue of $382.49M up 21.56% YoY

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal

Equity

Neutral Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

TEMTempus AI Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest TEM News